CLINIMIX N14G30

Main information

  • Trade name:
  • CLINIMIX N14G30
  • Dosage:
  • 8.5/30 %v/v
  • Pharmaceutical form:
  • Solution for Infusion
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • CLINIMIX N14G30
    Ireland
  • Language:
  • English

Status

  • Source:
  • HPRA - Health Products Regulatory Authority - Ireland
  • Authorization number:
  • PA0167/098/007
  • Authorization date:
  • 30-04-1996
  • Last update:
  • 14-10-2016

Summary of Product characteristics: dosage, interactions, side effects

PartII

SummaryofProductCharacteristics

1NAMEOFTHEMEDICINALPRODUCT

CLINIMIX ®

N14G30E,solutionforinfusion

2QUALITATIVEANDQUANTITATIVECOMPOSITION

CLINIMIX ®

N14G30Eispackagedinadualcompartmentplasticbagcontainingrespectivelyanaminoacidsolution

withelectrolytesandaglucosesolutionwithcalcium.

Theinjectableaminoacidsolutioncontains15L-aminoacids(8essentialaminoacids)neededfortheprotein

synthesis.

Theaminoacidprofileisthefollowing:

Essentialaminoacids/Totalaminoacids=41.3%

Essentialaminoacids/Totalnitrogen=2.83

Branchedchainaminoacids/Totalaminoacids=19%

ThequantitativecompositionofCLINIMIX ®

N14G30Eisthefollowing:

8.5%Aminoacid

solutionwithelectrolytes 30%Glucose

solution

withcalcium

Activeingredients

L-Leucine

L-Phenylalanine

L-Methionine

L-Lysine

(asL-Lysinechlorhydrate)

L-Isoleucine

L-Valine

L-Histidine

L-Threonine

L-Tryptophan

L-Alanine

L-Arginine

Glycine

L-Proline

L-Serine

L-Tyrosine

Sodiumacetate,3H

Dibasicpotassiumphosphate

Sodiumchloride

Magnesiumchloride6H

Glucose

(asmonohydrateglucose)

Calciumchloride,2H

6.20g/l

4.76g/l

3.40g/l

4.93g/l

(6.16g/l)

5.10g/l

4.93g/l

4.08g/l

3.57g/l

1.53g/l

17.6g/l

9.78g/l

8.76g/l

5.78g/l

4.25g/l

0.34g/l

5.94g/l

5.22g/l

1.54g/l

1.02g/l

300g/l

(330g/l)

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 09/03/2009 CRN 2062633 page number: 1

Aftermixingofthecontentsofbothcompartments,thecompositionofthebinarymixture,foralltheavailablebag

sizes,isthefollowing:

3PHARMACEUTICALFORM

Appearancepriortoreconstitution:Theaminoacidandglucosesolutionsareclearandcolourlessorslightlyyellow

Appearanceafterreconstitution:Clearandcolourlessorslightlyyellowsolution

4CLINICALPARTICULARS

4.1TherapeuticIndications

Parenteralnutritionwhenoralorenteralalimentationisimpossible,insufficient,orcontra-indicated.

Forpatientundergoinglong-termparenteralnutrition,theadditionofalipidemulsiontoCLINIMIX ®

inorderto

supplybothcaloriesandessentialfattyacidsispossible.

4.2Posologyandmethodofadministration

4.2.1Dosageandrateofinfusion

Thedosageischosenaccordingtothemetabolicneeds,theenergyexpenditureandtheclinicalstatusofthepatient.

Inadults,therequirementsrangefrom0.16gofnitrogen/kg/d(approximately1gofaminoacid/kg/d)to0.35gof

nitrogen/kg/d(approximately2gofaminoacid/kg/d).

Ininfants,therequirementsrangefrom0.35gofnitrogen/kg/d(approximately2gofaminoacid/kg/d)to0.45gof

nitrogen/kg/d(approximately3gofaminoacid/kg/d).

Thecalorierequirementsrangefrom25kcal/kg/dto40kcal/kg/d,dependingonthenutritionalstatusofthepatientand

thedegreeofcatabolism.Insomecases,theadditionofalipidemulsiontoCLINIMIX ®

isrecommended.

Therateofadministrationshouldbeadjustedaccordingtothedosage,thecharacteristicsoftheinfusedsolution,the

totalvolumeintakeper24hoursandthedurationoftheinfusion.Theinfusiontimeshouldbehigherthan8hours.

Themaximuminfusionrateis1.7ml/kg/houror100ml/hourto120ml/hour(forapatientweighing60kgto70kg).

Themaximumdailydoseis40ml/kgor2400mlto2800ml(forapatientweighing60kgto70kg).

4.2.2Routesofadministration

Theaminoacidandglucosesolutionsshouldbeinfusedviaacentralvein.

Theaminoacidandglucosesolutionsareusuallyadministeredtogetherwithalipidemulsion.Solutionsormixtures

N14G30

1l N14G30

1.5l N14G30

2l

Nitrogen(g)

Aminoacids(g)

Glucose(g) 7.0

10.5

14.0

Totalcalories(kcal)

Glucosecalories(kcal) 770

1155

1540

1200

Acetate(mmol)

Chloride(mmol) 34

Osmolarity(mOsm/l) 6

1270 6

1270 6

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 09/03/2009 CRN 2062633 page number: 2

4.3Contraindications

Knownhypersensitivitytoanyoftheingredients.

Renalfailureintheabsenceofhaemodialysis,haemofiltrationorhaemo-dia-filtration.

Severeliverdisease.

Aminoacidmetabolismdisorders

Metabolicacidosis,hyperlactataemia

Adrenalinsufficiency

Hyperosmolarcoma

Generalcontra-indicationsofaninfusiontherapysuchaspulmonaryoedema,hyperhydratationand

decompensatedcardiacinsufficiency.

CLINIMIX ®

withoutelectrolytesshouldnotbeusedincasesofhypokalaemiaandhyponatraemia.

CLINIMIX ®

containingelectrolytesshouldnotbeusedinpatientswithhyperkalaemiaandhypernatraemia.

4.4Specialwarningsandprecautionsforuse

Specialclinicalmonitoringisrequiredatthebeginningofanyintravenousinfusion.Shouldanyabnormalsign

occur,theinfusionmustbestopped.

Hypertonicsolutionsmaycausevenousirritationifinfusedintoaperipheralvein.Thechoiceofaperipheralor

centralveindependsonthefinalosmolarityofthemixture.

Thegeneralacceptedlimitforperipheralinfusionisabout800mOsm/lbutitvariesconsiderablywiththeage

andthegeneralconditionofthepatientandthecharacteristicsoftheperipheralveins.

Frequentclinicalevaluationandlaboratorydeterminationsarenecessaryforcorrectmonitoringduring

administration.Theseshouldincludebloodglucose,ionogramandkidneyandliverfunctiontests.

Theelectrolyterequirementsofpatientsreceivingthesolutionsshouldbecarefullydeterminedandmonitored

especiallyfortheelectrolyte-freesolutions.

Glucoseintoleranceisacommonmetaboliccomplicationinseverelystressedpatients.Withtheinfusionofthe

products,hyperglycaemia,glycosuria,andhyperosmolarsyndromemayoccur.Bloodandurineglucoseshould

bemonitoredonaroutinebasisandfordiabeticsinsulindosageshouldbeadapted,ifnecessary.

Fluidbalanceshouldbemonitoredduringtherapy.

Careshouldbetakentoavoidcirculatoryoverloadparticularlyinpatientswithcardiacinsufficiencyand/or

failure.

Inpatientswithhepaticinsufficiency,apartfromroutineliverfunctiontests,possiblesymptomsof

hyperammonaemiashouldbecontrolled.

Solutionscontainingelectrolytesmustbeinfusedwithcautioninpatientswithabnormallyhighserumlevelsof

theseelements,especiallyinpatientswithimpairedrenalfunction.

Iftheinfusionisnotcontinuousover24hours,keeptoanappropriateinfusionrate;possiblywithagradual

increaseinthefirsthourandagradualdecreaseinthelasthourtoavoidabnormalglycaemicpeaks.

Incaseofseverekidneyfailure,speciallyformulatedaminoacidsolutionsshouldbepreferred.

Vitaminsandtraceelementsshouldbeprovidedtopatientsreceivingparenteralnutritionforalongperiod.

4.5Interactionwithothermedicinalproductsandotherformsofinteraction

Notapplicable.

4.6Pregnancyandlactation

ThesafetyofCLINIMIX ®

inpregnancyandlactationhasnotbeenprovenduetothelackofclinicalstudies.The

prescribershouldconsiderthebenefit/riskrelationshipinordertoadministerCLINIMIX®topregnantorbreast

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 09/03/2009 CRN 2062633 page number: 3

4.7Effectsonabilitytodriveandusemachines

Notapplicable.

4.8Undesirableeffects

Theeffectswhichmayoccurandwhichrequirethetreatmenttobediscontinuedareasfollows:nausea,vomitingand

shivering.

Thesepotentialundesirableeffectsmayoccurasaresultofinappropriateuse:forexample,overdose,excessivelyfast

infusionrate(seesections4.4Specialwarningsandspecialprecautionsforuse,and4.9Overdosage)

Glucoseintoleranceisacommonmetaboliccomplicationinseverelystressedpatients.Withtheinfusionofthe

products,hyperglycaemia,glycosuria,andhyperosmolarsyndromemayoccur

4.9Overdose

Incasesofincorrectadministration(dosageandrate),signsofhypervolemiaandacidosismaybeobserved.

Hyperglycemia,glycosuria,andahyperosmolarsyndromemayoccurwithexcessiveglucoseinfusion.Atoorapid

infusionofaminoacidmayresultinnausea,vomitingandshivering.Insuchcases,discontinuetheinfusion

immediately.

Insomeseriouscases,haemodialysis,haemofiltrationorhaemo-dia-filtrationmaybenecessary.

5PHARMACOLOGICALPROPERTIES

5.1Pharmacodynamicproperties

Pharmacotherapeuticgroup:Solutionsforparentalnutrition/mixturesATCcode:B05BA10

Asaparenteralnutritionintravenousfluid,CLINIMIX ®

injectionsprovidenutritionalsupporttomaintainthecomplex

nitrogen-energybalancewhichmaybealteredbynutritionaldepletionandtrauma.CLINIMIX ®

solutionsprovidea

biologicallyavailablesourceofnitrogen(L-aminoacids),carbohydrates(asglucose)andelectrolytes.

5.2Pharmacokineticproperties

Theaminoacids,electrolytesandglucoseofCLINIMIX ®

aredistributed,metabolisedandexcretedinanidentical

mannertypicaltotheseparateaminoacids,glucoseandelectrolytesintravenoussolutions.

5.3Preclinicalsafetydata

Notapplicable

6PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Aminoacidssolution:

Aceticacid

Waterforinjections

Glucosesolution:

Hydrochloricacid

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 09/03/2009 CRN 2062633 page number: 4

6.2Incompatibilities

Additivesmaybeincompatible,refertothemanufacturerforfurtherdetails.

Ifadditivesarenecessary,compatibilitiesshouldbecheckedandthestabilityofmixturesshouldbecontrolled.

6.3ShelfLife

Forthedualbagsintheiroverpouch,theshelflifeis2years.

Afterthepeelsealactivation,chemicalandphysicalin-usestabilityhasbeendemonstratedfor7daysat2to8°

Cfollowedby48hoursbelow25°C.

Whenadditionshavebeenmade,fromamicrobiologicalpointofview,theadmixtureshouldbeused

immediately.Ifnotusedimmediately,in-usestoragetimesandconditionspriortousearetheresponsibilityof

theuserandwouldnormallynotbelongerthan24hoursat2to8°C,unlessadditionshavebeenmadeunder

controlledandvalidatedasepticconditions.Iflongerstorageperiodsarerequiredinexceptionalcircumstances,

thecompanycanbecontactedaschemicalandphysicalin-usestabilitydatafor7daysat2-8°Cfollowedby48

hoursbelow25°Careavailablefortheproductslistedinsection6.6.d.

6.4Specialprecautionsforstorage

Donotfreeze.

Fortheproductsuppliedintheclearoverpouch,keepcontainerintheoutercarton.

6.5Natureandcontentsofcontainer

CLINIMIX ®

N9G15Eispackagedinadualcompartmentplasticbagcontainingrespectivelyanaminoacidsolution

withelectrolytesandaglucosesolutionwithcalcium.

Thedualcontainerisamultilayerplasticbagpackagedinanoxygenbarrieroverpouch.Theoverpouchmayeitherbe

analuminisedplasticlaminateoraclearplasticlaminateonewithanoxygen-absorbingsachet.Thesachetmustbe

discardedafterremovaloftheoverpouch.Thebagmaterialisamultilayerplasticfilm,ofwhichtheinsidelayeris

EVA(ethylvinylacetate).Thebagwillbepresentedinoneoftwodesigns,horizontalpeelsealandverticalpeelseal

(seeFigures2and4respectively).Theplacementofbagportsisdependantuponthedesign.SeeFigures2and4.The

multilayerplasticiscompatiblewithlipids.

Bothcompartmentsareseparatedbyapeelseal.Justbeforeadministration,thecontentsofbothchambersaremixedby

squeezingorrollingthecompartmentstobreaktheseal.

3differentformatsareavailable:

1litre Packagesize:8

1.5litres Packagesize:6

2litres Packagesize:4

Thecompartmentsvolumesarethefollowing:

Notallpacksizesmaybemarketed

Figure1 Bagsize

Compartments 1l 1.5l 2l

Aminoacidssolution 500ml 750ml 1000ml

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 09/03/2009 CRN 2062633 page number: 5

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 09/03/2009 CRN 2062633 page number: 6

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 09/03/2009 CRN 2062633 page number: 7

6.6Specialprecautionsfordisposalofausedmedicinalproductorwastematerialsderivedfrom

suchmedicinalproductandotherhandlingoftheproduct

Donotuseunlesssolutionisclearandcontainerundamaged.

CLINIMIX ®

activationcanbeperformedintheoverpouchorafteritsremoval.Administertheproductonly

afterbreakingthesealandmixingthecontentsofbothcompartments.

Forsingleuseonly.Donotstorepartlyusedcontainersanddiscardallequipmentafteruse.Donotreconnect

partiallyusedbag.Donotconnectinseriesinordertoavoidairembolismduetopossibleresidualaircontained

intheprimarybag.

Aswithallparenteralsolutions,compatibilityshouldbecheckedwhenadditivesareused.Thoroughandcareful

asepticmixingofanyadditivesismandatory.

CLINIMIX ®

solutionsarepresentedintwodifferentbagsdesigns,seeSection6.5fordetails.Thedirectionforuse

hereafterappliesforbothdesigns.

a.Toopentheoverpouch

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 09/03/2009 CRN 2062633 page number: 8

Tomixsolutions

Ensurethattheproductisatroomtemperature.

Graspthecontainerfirmlyoneachsideofthetopofthebag.

Squeezetoactivate.(seefigure1or3).Productsuppliedwiththeverticalpeel-sealdesignmayalsobeactivated

byrolling(seeFigure3).

Mixbyinvertingthebag2or3times.

Preparationforadministration

Suspendthecontainer.

Removetheprotectivecoverfromtheadministrationportsite(thesmallerportofthepairoftheportsofthe

container,seefigure2or4).

Firmlyinserttheadministrationsetspikeintotheadministrationport.

AdditiontoCLINIMIX ®

(seesection6.2.also)

Warning:Thesupplementationcanbemade,eitherbeforeactivationofthecontainerinthedextrosesolutionfor

vitaminsonly,orafteropeningthepeelseals(oncethetwosolutionshavebeenmixed)foralladditives.CLINIMIX ®

maybesupplementedwith:

Lipidemulsions(forexampleClinOleic®)atarateof50to250mlperlitreofCLINIMIX®

Clinimix®N14G30

250mllipids20%* Clinimix®N14G30

1.5l

250mllipids20%* Clinimix®N14G30

500mllipids20%*

Nitrogen(g)

Aminoacids(g)

Glucose(g)

Lipid(g) 7.0

10.5

14.0

Totalcalories(kcal)

Glucosecalories(kcal)

Lipidcalories(kcal)

Glucose/lipidsRatio 1270

55/45 1655

64/36 2540

1200

1000

55/45

Acetate(mmol)

Chloride(mmol) 34

Osmolarity(mOsm/l) 6

1075 6

1130 6

1075

Sodium Potassium Magnesium Calcium

Uptoafinal

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 09/03/2009 CRN 2062633 page number: 9

Traceelements:perlitreofClinimix®

Vitamins:perlitreofClinimix®

StabilitydataforsupplementationofCLINIMIX ®

withothermarketedlipidemulsionsandotheradditivesornutrients

areavailableuponrequest.

Ifsomelightcreamingisobserved,mixthoroughlytheadmixturebygentleagitationtogetauniformemulsionbefore

theinfusion.

Additionsshouldbeperformedunderasepticconditions.

Additionscanbemadewithasyringeoratransferset.

Additionwithasyringeoratransfersetfittedwithaneedle

Preparetheinjectionsite(thesingleport,seefigure2or4).

Puncturetheportandinject.

Mixthesolutionsandtheadditives.

Additionwithatransfersetfittedwithaspike

Pleaserefertothe“Directionsforuse”ofthelipidtransfersetused.

Connectthespiketothetransfusionsite(thelongestport).

7MARKETINGAUTHORISATIONHOLDER

BaxterHealthcareLtd.,

CaxtonWay,

Thetford,

Norfolk,

IP243SE

UnitedKingdom

8MARKETINGAUTHORISATIONNUMBER

PA0167/098/007

9DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

Dateoffirstauthorisation: 30April1996

Uptoafinal

concentrationof Copper 10µmol Zinc 77µmol

Chromium 0.14µmol Manganese 2.5µmol

Fluorine 38µmol Cobalt 0.0125

µmol

Selenium 0.44µmol Molybdenum 0.13µmol

Iodine 0.5µmol Iron 10µmol

Uptoafinal

concentrationof vitaminA 1750IU Biotin 35µg

vitaminB6 2.27mg vitaminB1 1.76mg

vitaminD 110IU Folicacid 207µg

vitaminB12 3.0µg vitaminB2 2.07mg

vitaminE 5.1mg vitaminC 63mg

vitaminPP 23mg vitaminB5 8.63mg

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 09/03/2009 CRN 2062633 page number: 10

10DATEOFREVISIONOFTHETEXT

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 09/03/2009 CRN 2062633 page number: 11